Michael Derby Is Appointed Technical Director, Regulatory Approvals at Element Materials Technology

Michael Derby has been appointed technical director, regulatory approvals at Element Materials Technology.

Michael Derby served as Director for ACB Europe as well as a senior reviewer for the certification of wireless devices. In this role, he acted as a Telecommunication Certification Body for the Federal Communications Commission (US), a Certification Body for Innovation, Science and Economic Development (Canada), as well as a Notified Body for the European radio equipment directive. In addition to the 13 years spent in product certification and regulatory approval, his career includes 16 years working in commercial test laboratories, with 10 years in the UK and six years in California, US. Michael is one of the world’s leading experts on the integration of wireless modules into host equipment and lead author in both US and European guidance on the subject.

Steve Hayes, Technical Director, Connected Technologies at Element, commented: “We are delighted to add Michael’s industry-leading technical expertise to our rapidly expanding Connected Technologies team. His prolific experience and proven track record as a leading voice in the sector, as well as his profile as a world-renowned expert in the field, will prove invaluable to our ambitious growth strategy.”

Michael Derby added: “I am excited to be taking on the role of supporting Element’s highly knowledgeable team of engaged experts, many of whom not only hold wireless testing and consumer product compliance expertise but also sit on industry working groups and committees. I am looking forward to guiding Element’s team of specialists as they continue to play a first-hand role in the development of the standards we test to.”

Michael started his UK-based role at Element on 1 September and will be responsible for supporting global projects and customers, reporting to Steve Hayes, Element’s Group-wide Connected Technologies Technical Director. He will work closely with teams across Element’s global network of Connected Technology related laboratories and offices.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”